Stock 301301 YILI CHUANNING BIOTECHNOLOGY CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Yili Chuanning Biotechnology Co.,Ltd.

Equities

301301

CNE100005WX0

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-06-13 EDT 		5-day change 1st Jan Change
13.84 CNY +2.37% Intraday chart for Yili Chuanning Biotechnology Co.,Ltd. +5.73% +64.76%
05-14 Yili Chuanning Biotechnology Co.,Ltd. Approves Cash Dividend for the Year 2023 CI
04-21 Yili Chuanning Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 19,894 18,672 30,824 - -
Enterprise Value (EV) 1 19,894 18,672 30,824 30,824 30,824
P/E ratio 42.6 x 20 x 23.5 x 19.8 x 17.3 x
Yield - - - - -
Capitalization / Revenue - 3.87 x 5.46 x 4.89 x 4.46 x
EV / Revenue - 3.87 x 5.46 x 4.89 x 4.46 x
EV / EBITDA - 11.2 x 14.4 x 12.5 x 11.3 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - 2.68 x 3.77 x 3.23 x 2.78 x
Nbr of stocks (in thousands) 2,222,800 2,222,800 2,227,160 - -
Reference price 2 8.950 8.400 13.84 13.84 13.84
Announcement Date 3/12/23 4/10/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - 4,823 5,650 6,307 6,914
EBITDA 1 - 1,666 2,143 2,467 2,738
EBIT 1 - 1,121 1,555 1,846 2,098
Operating Margin - 23.25% 27.52% 29.27% 30.34%
Earnings before Tax (EBT) 1 - 1,118 1,550 1,842 2,093
Net income 1 411.5 940.6 1,314 1,558 1,771
Net margin - 19.5% 23.26% 24.71% 25.62%
EPS 2 0.2100 0.4200 0.5900 0.7000 0.8000
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 3/12/23 4/10/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - 14.3% 16.1% 16.4% 16.1%
ROA (Net income/ Total Assets) - 9.16% 12.3% 14.3% 14.2%
Assets 1 - 10,265 10,684 10,898 12,474
Book Value Per Share 2 - 3.130 3.680 4.290 4.970
Cash Flow per Share 2 - - 0.6300 0.7900 0.9100
Capex 1 - 345 590 488 436
Capex / Sales - 7.15% 10.45% 7.74% 6.31%
Announcement Date 3/12/23 4/10/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Yili Chuanning Biotechnology Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
13.84 CNY
Average target price
10.6 CNY
Spread / Average Target
-23.41%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
YILI CHUANNING BIOTECHNOLOGY CO.,LTD. Stock Yili Chuanning Biotechnology Co.,Ltd.
+64.76% 4.25B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+50.70% 791B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.96% 630B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.15% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.77% 328B
ABBVIE INC. Stock AbbVie Inc.
+8.79% 298B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.02% 246B
ROCHE HOLDING AG Stock Roche Holding AG
+1.27% 225B
NOVARTIS AG Stock Novartis AG
+11.95% 218B
AMGEN INC. Stock Amgen Inc.
+3.68% 160B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 301301 Stock
  4. Financials Yili Chuanning Biotechnology Co.,Ltd.